This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sandoz sues Amgen in US for blocking biosimilar rivals

( April 14, 2025, 10:08 GMT | Official Statement) -- MLex Summary: Biotech giant Amgen is facing an antitrust lawsuit in the US from Swiss generic and biosimilar specialist Sandoz, which accuses it of “extending and entrenching the dominant market position of its blockbuster medicine Enbrel.” Sandoz is seeking damages, as well as an injunction to stop Amgen from using “certain patent rights to block biosimilar competition,” including from Sandoz's biosimilar. The lawsuit was filed in the US District Court for the Eastern District of Virginia.* *Updated April 14, 2025, at 14:46 GMT: Removes reference to Erelzi launching in Europe, following a correction issued by Sandoz.  The statement follows....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login